GlassScriptPhysician profile
Robert Elmer Lee
NPI 1245234111
$1,431.12
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $355 · 2021: $470 · 2022: $162.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $285.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $257.28 | 2019-2020 | |
| Vifor Pharma, INC. | $222.70 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $143.63 | 2019-2021 | |
| Nxstage Medical, INC. | $83.65 | 2019 | |
| Amgen INC. | $65.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $64.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $62.82 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $51.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.44 | 2020-2021 | |
| Daiichi Sankyo INC. | $33.56 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $30.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.20 | 2022 | |
| Shire North American Group INC | $15.53 | 2019 | |
| Akebia Therapeutics INC | $15.48 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2021 | |
| Leadiant Biosciences, INC. | $13.34 | 2020 | |
| Calliditas Therapeutics US INC. | $12.10 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.